Axogen's third quarter 2026 revenue of $75.8M beat estimates by 45% while achieving GAAP profitability

Axogen reported record third quarter 2026 results characterized by significant top-line growth and a transition to GAAP profitability. Revenue surged 26.2% year-over-year to $75.8 million, driven by improved account productivity and expanding commercial insurance coverage, which now reaches 96% of covered lives in the U.S.

Key Highlights

• Revenue of $75.8 million substantially outperformed the consensus estimate of $52.4 million, led by broad-based growth across Extremities and Head and Neck segments.
• Achieved a milestone transition to GAAP net income of $2.3 million ($0.04 per share), compared to $0.7 million in the prior year period.
• Raised full-year 2026 revenue guidance to at least $290 million, representing minimum growth of 29%, supported by both organic strength and the recent BioCircuit acquisition.
• Completed an upsized public offering during the quarter, generating $225 million in net proceeds and ending the period with a robust cash position of $350.1 million.